Is Cardarine a SARM?

Why is Sports Technology Labs the best place to buy Cardarine online?

A recent study involving chemical analyses of 44 different products sold and marketed as SARMs on the internet revealed that quality control in this industry varies significantly from one company to the next. Only 52% of the products tested contained the product advertised, 59% contained amounts that differed from the label, a shocking 39% contained other unapproved drugs, 25% contained substances not listed on the label, and 9% contained no active substance at all. It is critical when performing research with SARMs to only purchase the highest quality, verified by third-party analysis.

If you are trying to figure out where to buy Cardarine, which many researchers consider one of the best SARMs for cutting body fat, there appears to be no shortage of options out there. Sports Technology Labs is the best place to buy Cardarine online because of their consistent, verifiable, high-quality products, safe bottling and packaging, fast shipping, and excellent customer service. Our Cardarine is also available in pure powder form.

When you buy SARMs from Sports Technology Labs, you are choosing the highest quality ingredients. Minimum 98% pure compounds tested and certified by accredited American third-party labs, suspended in USP-grade (the highest grade) PEG-400, bottled in America. Our products come in glass bottles with fixed glass droppers to prevent the leaching of unwanted plasticizers like BPA, and to avoid contamination by eliminating the need for external measuring tools.

At Sports Technology Labs, you can find SARMs for sale, including the highest quality Cardarine available online. That’s why we are confident in our claim that we offer the best GW-501516 for sale on the market today. 

Certificate Of Analysis

All Sports Technology Labs SARMs are third-party tested by MZ Biolabs, an independent laboratory based in Arizona. Each batch is bottled and tested in the USA to ensure accuracy and purity. Our Certificates of Analysis confirm that products meet the listed specifications:

• Date: 07/06/25
• Purity Level: 99.57%

Introduction to Cardarine (GW-501516)

Cardarine (GW-501516), also referred to as GW1516, is a synthetic PPARδ (Peroxisome Proliferator-Activated Receptor delta) agonist developed in the early 1990s through pharmaceutical research programs, including those by GlaxoSmithKline. It was originally investigated as a potential treatment for metabolic and cardiovascular diseases, including heart disease, dyslipidemia, and type 2 diabetes. Early animal research and short-term human clinical trials suggested that GW-501516 could enhance fatty acid oxidation, improve energy expenditure, and influence lipid metabolism, making it a subject of ongoing interest in metabolic research.

Unlike selective androgen receptor modulators (SARMs), Cardarine does not act on androgen receptors. Instead, it binds to and activates PPARδ, a nuclear receptor that regulates the transcription of genes involved in fatty acid transport, lipid catabolism, glucose uptake, mitochondrial function, and energy metabolism. Activation of these pathways has been shown in preclinical models to shift skeletal muscle toward greater fatty acid utilization, improve endurance capacity, and stabilize metabolic efficiency. These mechanisms explain why Cardarine has been widely discussed in both scientific literature and athletic performance communities.

However, these findings must be understood in context. Human clinical trials were discontinued after long-term rodent studies found rapid development of cancers in multiple organs, including the liver, stomach, and thyroid, at high experimental doses. Additional studies raised concerns about liver toxicity, blood lipid alterations, and other health risks associated with prolonged exposure. Because of these safety concerns, the World Anti-Doping Agency (WADA) has banned GW-501516, and several endurance athletes have tested positive for Cardarine, resulting in strict anti-doping sanctions. Regulatory agencies, including the U.S. FDA, have not approved Cardarine for human use. It is not a dietary supplement and is not legally marketed as one in the United States.

Despite these warnings, Cardarine is sometimes misrepresented online as a weight-loss or endurance aid. Some retailers sell GW-501516 in powder form or as a liquid research chemical, promoting claims related to fat burning, weight loss, and workout performance. These claims are based largely on preclinical animal studies and short-term trials, and do not constitute medical advice or evidence of safety. Reported adverse effects include stomach pain, liver toxicity, and carcinogenicity in animal studies, making the risks far outweigh any unproven benefits.

In summary, Cardarine GW-501516 is a research compound that acts as a potent PPARδ agonist, influencing genes involved in energy metabolism and fatty acid oxidation. While it remains of interest for experimental models studying lipid metabolism, endurance physiology, and insulin sensitivity, its use in humans is associated with serious health risks. GW-501516 is not FDA-approved, not a supplement, and is intended strictly for laboratory research. All research involving this compound should follow applicable regulations, controlled dosing protocols, and institutional safety guidelines to minimize risk and maintain research integrity.

Mechanism of Action

Cardarine (GW-501516, also referred to as GW1516) is a small-molecule PPARδ (Peroxisome Proliferator-Activated Receptor delta) agonist developed in the early 1990s through pharmaceutical research programs. It exhibits low-nanomolar potency for PPARδ with marked selectivity over PPARα and PPARγ in co-activator and reporter assays. This selectivity underpins its use as a research tool in metabolic and endurance-related pathways.

Cardarine functions as a metabolic modulator by binding to PPARδ nuclear receptors. Once activated, these receptors regulate the transcription of genes involved in lipid catabolism, fatty acid oxidation, glucose uptake, mitochondrial function, and overall energy metabolism. Activation of PPARδ is associated with recruitment of the coactivator PGC-1α, which in turn enhances the expression of proteins linked to energy expenditure and oxidative metabolism. This signaling can intersect with AMPK–PGC-1α regulatory networks in some models, though GW-501516 is not a direct AMPK activator.

In preclinical animal models, Cardarine has been observed to shift skeletal muscle toward greater utilization of fatty acids as an energy substrate, supporting improved oxidative capacity and endurance-related metabolic changes. These mechanistic findings have made GW-501516 a frequent subject of experimental research on metabolic regulation, endurance physiology, and lipid metabolism.

How Cardarine Works

Cardarine, also known as GW-501516, is a synthetic compound that exerts its effects by selectively activating the peroxisome proliferator-activated receptor delta (PPARδ). This receptor plays a pivotal role in regulating the body’s metabolism, particularly in tissues with high energy demands such as skeletal muscle and the heart. When Cardarine binds to PPARδ, it triggers a cascade of gene expression changes that enhance the breakdown and utilization of fatty acids, boost mitochondrial function, and support overall energy balance.

By promoting the β-oxidation of fatty acids, Cardarine helps the body convert fat into usable energy more efficiently, which can lead to improved physical performance and enhanced endurance. This metabolic shift has been associated in preclinical studies with improved endurance performance and more favorable lipid profiles, which are of interest in cardiometabolic research contexts. Unlike selective androgen receptor modulators (SARMs), Cardarine does not interact with androgen receptors or influence hormone levels; instead, it acts as a metabolic modulator, fine-tuning the body’s energy systems at the cellular level. As a result, GW-501516 has become a widely discussed compound in research circles for its potential to support metabolism, energy expenditure, and overall health.

Function of PPAR Agonists

Data indicates that PPAR activity preserves glucose for use in tissues like the brain while promoting the mobilization of fatty acids for muscular endurance. PPAR has also been observed to play an important role in temperature regulation, inflammation mediation, mitochondrial respiration, keratinocyte differentiation, and skin and muscle repair. Molecular analyses revealed that PPAR regulates the expression of genes associated with contractile proteins, lipid oxidation, and mitochondrial biogenesis.

PPAR Effects during Fasting

The effects of PPAR are observed in particular during fasting, when free fatty acids are released into the blood. A study in PPAR-null mice demonstrated that the absence of PPAR results in elevated free fatty acids during fasting, lipid accumulation in the liver and heart, low blood sugar, low body temperature, ketones in urine, and ultimately a premature death. Mice naturally adapt to high free fatty acid levels during fasting through the induction of cardiac and hepatic PPAR genes that improve fatty acid uptake and oxidation.

The benefits and side effects of GW-501516, however, have not been confirmed by the Food and Drug Administration (FDA), and like other SARMs for sale, it should be used for research purposes only. Due to its tendency to increase endurance and energy, the World Anti-Doping Agency (WADA) has banned the use of Cardarine in professional sports, and several athletes have tested positive for Cardarine and were dismissed, as this chemical is only for researchers and clinical trials.

Research Applications

Cardarine (GW-501516) has attracted significant attention in both animal research and early human clinical trials for its potential to address a range of metabolic and cardiovascular conditions. While initial clinical investigations provided limited early data, the vast majority of findings to date come from preclinical and mechanistic studies conducted in animals and in vitro models. These results should not be interpreted as evidence of safety or efficacy in humans, and Cardarine remains an investigational compound that has not been approved for medical use.

Early research explored its potential in the context of obesity, diabetes, dyslipidemia, and cardiovascular disease, examining its ability to reduce body fat, improve insulin sensitivity, and influence metabolic function under controlled experimental conditions. Although clinical development was ultimately halted due to findings of liver toxicity and rapid cancer development in multiple organs in long-term rodent studies, Cardarine remains a widely discussed topic in the scientific community for its role in studying PPARδ activation and metabolic regulation.

In the context of athletic performance research, preclinical exercise models have investigated whether PPARδ activation by GW-501516 may influence energy balance, fat oxidation, and endurance-related pathways. Importantly, these effects have only been observed in controlled experimental systems, and no approved human applications exist. While such findings have informed ongoing research into fat metabolism, body composition, and performance physiology, they should not be interpreted as established human benefits.

It is essential to emphasize that Cardarine is not approved for human consumption, is not a dietary supplement, and must not be used outside of legitimate research environments. Ongoing studies continue to explore its effects on metabolic pathways, body composition, and cardiovascular health within preclinical frameworks, but all use should remain strictly within the boundaries of controlled scientific investigation.

Research Applications (Preclinical Context)

Research on Cardarine has investigated several key areas:

• Lipid Metabolism and Energy Balance: Studies in cell and animal models have examined effects on fatty acid transport, oxidation, and mitochondrial activity, including preclinical evidence of changes in fat oxidation and body fat regulation.
• Glucose Metabolism and Insulin Resistance: Preclinical data suggest that Cardarine may affect glucose uptake and insulin sensitivity in experimental models. However, this has not been confirmed in long-term human studies.
• Endurance and Physical Performance: Animal research has evaluated PPARδ activation in pathways associated with increased endurance and exercise capacity, including mechanisms relevant to skeletal muscle substrate use.
• Cardiometabolic Models: Experimental models have explored changes in lipid profiles, inflammatory markers, and vascular health parameters that may be relevant to metabolic and cardiovascular research.

These research applications are preclinical only. Cardarine is not approved as a drug, dietary supplement, or performance enhancer, and it should only be used under controlled laboratory conditions for legitimate research purposes.

Clinical Studies

Early human clinical trials of Cardarine were conducted to explore its potential in treating metabolic and cardiovascular disorders, including obesity and dyslipidemia. Short-term studies showed increases in HDL cholesterol, but development was halted in 2007 after long-term rodent studies revealed multi-organ tumor formation at high exposures. No long-term safety data in humans are available.

Cardarine is not FDA-approved, not a dietary or sports supplement, and banned by the World Anti-Doping Agency (WADA) due to its performance-enhancing potential. Several athletes have tested positive for GW-501516 in doping controls, resulting in sanctions. In many jurisdictions (including Australia), Cardarine is illegal to sell or supply for human use.

Several animal studies have been performed that point to Cardarine’s ability to enhance specific physiological processes related to energy metabolism, as well as potential improvements in blood lipids:

• One study on mice found that GW-501516 promotes fatty acid oxidation and fat burning in skeletal muscle tissue and alleviates metabolic syndrome.
• Another study found that peroxisome proliferator-activated receptors can significantly enhance running endurance in Kunming mice.
• Yet another study on mice revealed that PPARs augment exercise endurance by preventing the exhaustion of glucose (“hitting the wall”).
• A study involving obese rhesus monkeys found that GW-501516 increased high-density lipoprotein (HDL) and lowered very-low-density lipoprotein (VLDL), indicating potential cardioprotective effects from Cardarine.
• Two separate phase II clinical studies found positive effects of Cardarine on obesity, diabetes, dyslipidemia, and cardiovascular disease, as well as suppression of macrophage-derived inflammation.
• A study in rats fed a high-fructose diet found that GW-501516 reduced inflammatory markers, especially in the liver, and increased the expression of genes that regulate beta-oxidation.

Side Effects

While Cardarine is not known to cause androgenic side effects like anabolic androgenic steroids, data in rats indicates that doses of 3 mg/kg/day (180-240 mg per day in the average 60-80 kg adult), significantly higher than those used in mammalian trials, caused cancer to develop quickly in several organs. Anecdotal data online indicates a few noticeable side effects. Still, more research is necessary to determine the overall safety profile of GW-501516 before it can be approved for human use by the FDA.

Product Data

• CAS Number: 317318-70-0
• Molecular Formula: C₂₁H₁₈F₃NO₃S₂
• Molar Mass: 453.5 g/mol
• Half-life (reported): 16–24 hours (model-dependent)
• Class: PPARδ Agonist (Metabolic Modulator)
• Intended Use: Laboratory research only; not for human or veterinary use

Storage: Store in a cool, dry place away from direct sunlight to maximize shelf life.

• 30 mL of liquid Cardarine per bottle, containing 20 milligrams per milliliter.
• Includes a graduated 1 mL glass pipette for convenient measurement.
• Glass bottle with UV resistance to minimize degradation.
• Tamper-proof seal to ensure safety in transit.
• Less than 5% variance in concentration, guaranteeing consistency.
• Formulated and packaged to prevent evaporation in storage.

SKU: 2

Safety Considerations

The safety profile of Cardarine (GW-501516) is a critical area of concern, largely informed by preclinical animal studies rather than large-scale human clinical data. Long-term rodent research identified liver toxicity and the development of cancers in multiple organs at relatively high doses and extended exposure durations. These findings led to the termination of Cardarine’s clinical development programs and continue to shape the regulatory stance on this compound.

Cardarine has been classified as a prohibited substance by the World Anti-Doping Agency (WADA) due to its potential health risks, performance-enhancing effects, and the absence of sufficient human clinical trials to establish a comprehensive safety profile. Reported adverse effects from limited human exposure and anecdotal reports include stomach pain, headaches, and in more severe cases, organ toxicity. The preclinical toxicology data—particularly findings of rapid tumor development in rodent studies—remain a central reason why Cardarine is not approved for medical or dietary use.

Because Cardarine is not considered safe for human consumption, is not FDA-approved, and is not a dietary supplement, any handling or study of the compound should occur strictly within controlled laboratory research settings. The risks associated with improper or unsupervised use highlight the importance of sourcing only high-purity, third-party tested Cardarine from reputable suppliers. Counterfeit, contaminated, or substandard products circulating through unregulated markets can significantly increase the risk of adverse effects.

It is also important to clarify that no approved human dosing protocols exist, and any discussion of dosage should remain confined to preclinical research contexts. As with any experimental compound, appropriate laboratory safety procedures, institutional oversight, and adherence to all regulatory requirements are essential. Consultation with qualified professionals is strongly advised before initiating any research involving GW-501516 to ensure compliance and minimize potential harm.

Safety Information (Non-Clinical)

• Carcinogenicity: High-dose, long-duration rodent studies observed rapid development of tumors in multiple organs (e.g., liver, stomach, thyroid).
• Hepatotoxicity: Preclinical and case literature indicate potential liver stress and elevated liver enzymes.
• Cardiometabolic Effects: Effects on blood pressure, blood lipids, and heart health remain under investigation.
• Unknown Human Safety: There is no approved therapeutic use, and long-term human safety data are lacking.

Cardarine is not known to cause androgenic effects like anabolic steroids, but its unapproved status and preclinical risk profile warrant caution. Excessive intake in experimental settings has been associated with increased health risks, emphasizing the importance of controlled dosing and adherence to research protocols.